NCT02355821 - Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women | Biotech Hunter

Enrollment

114

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 15, 2018

Study Completion Date

July 10, 2018

Conditions

OsteopeniaArterial Hypertension

Interventions

DRUG

Moxonidine

0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D

DRUG

Bisoprolol

5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D

Trial Locations (1)

101000

National Research Center for Preventive Medicine, Moscow